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Myocardial stretch induces a two-phase increase in developed force. The first phase occurs 
immediately, is due to an increase in myofilament Ca2+ responsiveness, and is the expression of 
the Frank-Starling mechanism. The second phase, gradually developed, results from an increase 
in intracellular Ca2+ concentration and is known as “slow force response” (SFR) to stretch. 
Characterization of the subcellular basis of the increase in Ca2+ responsible for the SFR 
development was an important objective of our laboratory group during last two decades. We 
have compiled enough evidence to suggest that the SFR is the mechanical expression of an 
autocrine/paracrine loop of intracellular signals leading to the reactive oxygen species (ROS)-
mediated activation of redox-sensitive kinases that activate (phosphorylate) the cardiac Na+/H+ 
exchanger (NHE1), increasing intracellular Na+, and consequently, Ca2+ concentration. 
Recently, we demonstrated that mineralocorticoid receptor (MR) activation after stretch is 
critical for the progression of this complex signaling pathway. Interestingly, clinical evidence 
assigns a detrimental role to MR activation in the pathophysiology of heart failure (HF), in 
which cardiac wall stretch is an important triggering factor. The aim of this mini-review is not 
only to share our own experience describing novel non-genomic effects of MR activation after 
acute myocardial stretch and the physiological consequences, but also to discuss other possible 
pathophysiological implications, as well as the potential clinical impact of this important 
discovery. 
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During last two decades, our laboratory group focused on exploring early intracellular signals 
triggered by myocardial stretch. We were particularly interested in describing acute intrinsic 
mechanisms of the heart to adapt cardiac output to changes in hemodynamic conditions, but also 
to explore its potential pathological consequences if stretch persists over time. A sudden 
increase in left ventricular end-diastolic volume (wall stretch) caused by either increasing aortic 
resistance to ejection or venous return, immediately leads to a more powerful contraction. This 
increase in developed force occurs in two phases: A rapid one that constitutes the well-known 
Frank-Starling mechanism attributed to enhanced myofilament responsiveness to Ca2+, and the 
SFR that is gradual and due to an increase in Ca2+ transient amplitude. Characterization of the 
subcellular basis of this increase in Ca2+ responsible for the SFR development was the area of 
research in which we have been working for almost 20 years. We were able to unveil a complex 
autocrine/paracrine signaling pathway underlying this slow increase in cardiac contractility, that 
may also be responsible for triggering cardiac hypertrophy (CH) and HF when sustained over 
time (for review see [1]). Briefly, the mechanism comprises: (1) Stretch-triggered release of 
Angiotensin II (Ang II)/activation of AT1 receptors, (2) release/formation of endothelin 
(ET)/activation of ETA receptors, (3) MR activation, (4) transactivation of the epidermal growth 
factor receptor (EGFR), (5) increased formation of mitochondrial ROS, (6) activation of redox-
sensitive kinases upstream NHE1, (7) NHE1 activation, (8) increase in intracellular Na+ 
concentration, and (9) increase in Ca2+ transient amplitude through the Na+/Ca2+ exchanger. 
Among our latest contributions to understand this striking signaling pathway, the finding of the 
critical role played by an increased ROS production[2], together with the demonstration that 
non-genomic effects of MR activation are essential to trigger these ROS [3, 4], are probably the 
most important ones. The next sections will mainly focus on our own experience regarding non-
genomic effects of MR activation following acute myocardial stretch. We will briefly discuss 
its physiological and pathophysiological consequences, as well as the potential clinical 
implications of this important discovery. 
 
Making a long story short 
 
Several years ago, elegant experiments by Cingolani et al [5] in isolated cat cardiomyocytes 
demonstrated that Ang II, in a concentration that well resembles the physiological one, increased 
sarcomere shortening entirely through an autocrine crosstalk with endogenous ET. Interestingly, 
a rise in mitochondrial ROS production accompanied this effect, which was on the other hand 
cancelled by preventing oxidative stress, clearly revealing a cause-effect relationship. [5] Since 
we had previously provided evidence that Ang II/AT1 receptor activation constitutes the initial 
step in the signaling pathway leading to the SFR, we hypothesized that an increase in ROS 
production could be part of this signaling cascade. Certainly, we subsequently found that the 
SFR was accompanied by an increased ROS production that promoted NHE1 activation [2]. 
Conversely, the suppression of ROS production by either scavengers or inhibitors of its 
formation cancelled the SFR, [2], once again unveiling a cause-effect relationship. Consistently, 
we demonstrated that stretch stimulated the redox-sensitive kinase cascade of ERK1/2-p90RSK 
increasing its phosphorylation level, effect that was suppressed by AT1-receptor blockade with 
losartan. We were also able to demonstrate the mitochondrial origin of ROS that were triggered 
by a small amount of NADPH oxidase-derived ROS, [2], in a mechanism that clearly reminds 
the so-called “ROS-induced ROS-release” phenomenon described by others. [6, 7].  




The question regarding to the reasons for exploring the putative activation of MR following 
myocardial stretch may be certainly asked. Two lines of existing evidence induced us to 
investigate the possible participation of the MR in the signaling cascade leading to the SFR 
development: (1) The confirmed link between Ang II-AT1 receptor and the MR, [8-10] (2) The 
fact that EGFR transactivation (that is part of the route leading to the SFR [11, 12]) can be 
triggered by MR activation. [8, 13, 14]. We initially demonstrated that MR activation is 
necessary to promote ROS formation by a physiological concentration of Ang II, since the effect 
was cancelled by blocking the MR with spironolactone or eplerenone.[3] As expected, the 
increase in ROS production was cancelled by antagonizing AT1 receptors, but also by ET1 (type 
A) receptor blockade, by preventing EGFR transactivation, by inhibiting NADPH oxidase, or 
by targeting mitochondria, while it was unaffected by glucocorticoid receptor (GR) inhibition. 
[3]. Interestingly, an increased ROS production promoted by an equipotent dose of aldosterone 
(ALD) was prevented by blocking the MR (eplerenone), but not by inhibiting GR or protein 
synthesis, suggesting that it was a specific and non-genomic MR effect. [3] On the other hand, 
ALD also increased the phosphorylation level of the redox-sensitive kinases ERK1/2-p90RSK, 
and the NHE1, effects that were all eliminated by eplerenone or by preventing EGFR 
transactivation. [3] We subsequently proved the cancellation of the SFR either by 
pharmacological MR blockade [3] or the specific silencing of MR expression (interference 
RNA), [4] but not by GR blockade or protein synthesis inhibition. [3]. Taken together, these 
results clearly demonstrated that post-stretch MR activation is crucial to trigger mitochondrial 
ROS formation leading to NHE1 activation, and hence, to the development of the SFR. Figure 
1 summarizes the most representative findings that support our conclusions, by compiling 
original force records of isolated papillary muscles subjected to a sudden increase in length 
under four different experimental conditions. While the “upper left” panel shows the classical 
force response to stretch consisting of an initial rapid phase followed by the SFR, the other 
panels show the cancellation of the SFR by silencing MR expression, preventing mitochondrial 
ROS formation, or silencing NHE1 expression. For a better comprehension of the complex 
sequence of events triggered after myocardial stretch, see the scheme depicted in Figure 2.  
 
MR activation in the myocardium: Facts and doubts 
 
Figure 1. Original force records of 
isolated papillary muscles subjected to a 
sudden increase in length under different 
experimental conditions. Upper left 
(“control”): Classical two-phase force 
response to stretch consisting of an initial 
rapid one followed by the SFR. Upper 
right: Cancellation of the SFR in muscles 
with silenced MR expression. Bottom 
left: Cancellation of the SFR by 
preventing mitochondrial ROS formation. 
Bottom right: Cancellation of the SFR in 
muscles with silenced NHE1 expression. 
(Adapted from: Pérez NG et al. J. Appl. 
Physiol. 111[3]: 874, 2011 -upper left and 
bottom right-, Díaz RG et al. Hypertension 
63: 112, 2014 -upper rigth-, and Caldiz CI 
et al. J. Physiol. 584.3: 895, 2007 -bottom left-).      
 




In order to better comprehend the possible role played by the MR in cardiac 
physiology/pathophysiology, it is important to clarify some general aspects concerning the 
receptor activation. The MR is a member of the steroid/thyroid hormone receptor superfamily 
of ligand-inducible transcription factors that mediates classic ALD effects. Although the 
increase in ALD concentration constitutes the best-recognized stimulus to MR, it can be also 
activated in normal or even low-ALD states. [15, 17] Moreover, the MR was shown to have 
equivalent high affinity for ALD, cortisol and deoxycorticosterone. [18] This is extremely 
important since circulating glucocorticoid levels are greater than those of ALD determining that 
MR are usually occupied, but not activated, by glucocorticoids. However, under pathological 
conditions and increased oxidative stress glucocorticoids have been shown to activate the 
MR.[19] Interestingly, in epithelial ALD-target cells, the highly expressed 11β-hydroxysteroid 
dehydrogenase enzyme (11βHSD2) facilitates ALD occupancy and activation of the MR, by 
converting active glucocorticoids (e.g. cortisol) into receptor-inactive 11-keto analogs (e.g. 
cortisone), significantly reducing intracellular glucocorticoid levels (to ~10-fold those of 
ALD).[20-22] In contrast, in non-epithelial tissues such as hippocampus, vascular smooth 
muscle, fat or the myocardium (of particular interest for us), the expression of 11βHSD2 is too 
low to prevent cortisol access to the MR in competition with much lower concentrations of 
ALD. Therefore, the question as to how ALD can occupy and activate the MR in tissues with 
very low expression of 11βHSD2 as the myocardium is still unanswered. However, in light of 
our recent findings, the activation of the MR following myocardial stretch appears 
unquestionable.[3, 4] In this context, it seems reasonable to consider any of the following 
possibilities for ALD-independent MR activation: (1) Glucocorticoid-mediated MR activation, 
especially under conditions of enhanced ROS production, as reported by Mihailidou et al.[23] 
(2) ligand-independent MR activation as the redox-sensitive Rac1-dependent activation 
proposed by Nagase et al.[23] (3) Direct MR phosphorylation independent of its own ligand, as 
proposed by Kato et al.[24] for the estrogen receptor. (4) Specific changes in MR conformation 
induced by strain, as proposed by Zou et al. [25] to explain AT1 receptor activation by 
mechanical stretch. In summary, we have provided enough evidence to state that activated MR 
is required for the effect of stretch on cardiac force. Unfortunately, whether the mechanism 
involves an autocrine/paracrine effect of ALD, or an ALD-independent pathway remains to be 
elucidated.  
 
Physiological and pathophysiological consequences of myocardial MR activation. 
Potential clinical implications. 
Physiologically, the SFR constitutes a powerful mechanism occurring just after the Frank-
Starling mechanism took place by which the heart adapts to an abrupt increase in afterload. 
However, crucial events leading to the increase in intracellular Ca2+ concentration responsible 
for the SFR development (AngII/ET release, MR activation, increased oxidative stress and 
NHE1 hyperactivity, Figure 1 and 2) are also critically involved in the progression of 
pathological CH and HF (for review see [26, 28]). In this context, it is attractive to hypothesize 
that mechanical stress may not only trigger immediate intrinsic heart mechanisms to adapt 
cardiac output to changes in hemodynamic conditions, but also constitutes the first step toward 
pathologic cardiac remodeling if the initial events are sustained over time (chronic wall stretch). 
CH and HF are two of the most important health problems in western societies. Current 
treatment against these pathologies is primarily based on preventing the action of hormones 
including AngII, catecholamines and ALD. Regarding ALD antagonism, the widely used term 




“ALD inhibition” should be replaced by “MR antagonism”, since as stated before, experimental 




Figure 2. Schematic representation of the intracellular sequence of events triggered by myocardial stretch. 
 
The striking benefits of MR antagonists in HF patients have been demonstrated by several 
studies. The first MR antagonist accepted for clinical use in humans was “spironolactone”, 
which despite some tolerability problems was approved to be tested in patients with severe HF 
(Class III-IV of the New York Heart Association “NYHA”) in the RALES (Randomized 
Aldactone Evaluation Study) clinical trial. An interim analysis revealed a ~30% reduction in the 
relative risk of death in spironolactone-treated patients, [19] together with an equal and 
impressive reduction in hospitalization for cardiac reasons. This excellent prove of efficacy of 




MR antagonism provoked a premature termination of the trial. Afterward, the EPHESUS 
(Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) 
clinical trial tested the effect of eplerenone, a more specific MR antagonist, in patients with 
acute myocardial infarction with left ventricular systolic dysfunction. Treatment started 3 to 14 
days after infarction and was maintained during 16 months, revealing a reduction of ~15% in 
all-cause mortality and ~21% in sudden cardiac death. [30] More recently, the effect of 
eplerenone in patients with less severe HF was proved in the EMPHASIS-HF (Eplerenone in 
Mild Patients Hospitalization and Survival Study in Heart Failure) clinical trial. This study 
enrolled patients with HF class II-III of the NYHA and left ventricular ejection fraction of no 
more than 35%. Once again, the study was stopped prematurely due to the outstanding benefit 
obtained by eplerenone therapy in terms of reduction of cardiovascular death risk and 
hospitalization. [31] The treatment was then extended to both arms of the trail.  
In contrast to the beneficial effects observed in the three previous clinical trials, in the TOPCAT 
(Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) study, 
spironolactone failed to improve clinical outcomes in patients with symptomatic HF and 
relatively preserved ejection fraction (≥45%). [32] Researchers argued that since the study 
enrolled patients from six different countries, regional heterogeneity of practice patterns and/or 
accuracy of diagnosing methods to identify this subgroup of HF patients might have conspired 
to reach reliable results. In fact, they could observe beneficial treatment effects in patients 
coming from American countries that were not observed in those from Russia and Georgia. 
The most recent one is the ALBATROSS (Aldosterone Lethal effects Blockade in Acute 
myocardial infarction Treated with or without Reperfusion to improve Outcome and Survival at 
Six months follow-up) study. It failed to show benefits of early MR blockade (single intravenous 
bolus of potassium canrenoate followed by oral spironolactone for 6 months) in patients 
admitted for myocardial infarction irrespective of the presence of HF or left ventricular 
dysfunction. [33]  
The results of the last two clinical trials clearly limit general conclusions about the effects of 
MR antagonism in cardiac pathologies. However, the methodological uncertainties associated 
with TOPCAT, and the completely different target population enrolled for ALBATROSS at 
least invite us to propose separated conclusions. On the one hand, while clinical evidence 
appears to undoubtedly demonstrate beneficial effects of MR blockade in patients with severe 
HF, further investigation is needed to precisely clarify its role in those patients with relatively 
preserved ejection fraction. On the other, the treatment clearly lacked of benefits when applied 
just after myocardial infarction irrespective of patient’s ventricular function. 
Beyond these controversies, the mechanisms by which MR antagonism provide cardiovascular 
protection in certain group of HF patients are not completely understood, and the clinical use of 
these compounds remains lower than expected. In this context, the demonstration in our basic 
research studies that MR activation after acute myocardial stretch is a crucial early signal to the 
development of the SFR may shed some light to understand the role of MR activation in cardiac 
pathophysiology. In this regard, it is tempting to suggest that prevention of oxidative stress with 
the consequent prevention of NHE1 activation should be considered as a potential key factor for 
the salutary effects of MR antagonism in humans. 
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